RLMD
RELMADA THERAPEUTICS, INC.Company Information
- Company Name
- RELMADA THERAPEUTICS, INC.
- CIK
- CIK0001553643
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- RLMD: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- RLMD
SEC filing data through
Insider Sentiment
- Last purchase
- 2026-09-10
- Last sale
- —
- Shares purchased (TTM)
- 1,217,465
- Shares sold (TTM)
- 0
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 100,372,189
- Shares outstanding
- 112,375,941
- Ownership
- 89.32%
Earnings Market Reaction
- Filing date
- 2026-08-06
- Price on filing date
- —
- 1-month reaction
- -19.37%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Preferred Class A | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | ||||||
| Convertible Preferred Stock | 0 | 0 | 0 | - | - | - | 0 | - | - | - | - | - | ||||||
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 11 | 10 | 3 | 1 | 1 | 1 | 4 | 1 | 2 | 1 | 4 | 7 | ||||||
| Short Term Investments | 206 | 224 | 90 | 13 | 19 | 26 | 41 | 53 | 68 | 82 | 92 | 100 | ||||||
| Accounts And Other Receivables Net Current | 0 | - | - | - | - | - | - | - | - | - | - | - | ||||||
| Prepaid Expense Current | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 2 | 1 | 1 | 1 | 3 | ||||||
| Assets Current | 219 | 235 | 94 | 15 | 21 | 28 | 46 | 56 | 71 | 84 | 98 | 109 | ||||||
| Other Assets Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Assets | 219 | 235 | 94 | 15 | 21 | 28 | 46 | 56 | 71 | 84 | 98 | 109 | ||||||
Liabilities And Stockholders Equity | ||||||||||||||||||
| Accounts Payable Current | 2 | 6 | 2 | 1 | 1 | 1 | 4 | 2 | 4 | 5 | 4 | 3 | ||||||
| Accrued Liabilities Current | 5 | 7 | 5 | 4 | 4 | 4 | 6 | 6 | 5 | 7 | 9 | 6 | ||||||
| Liabilities Current | 7 | 13 | 6 | 5 | 5 | 5 | 10 | 8 | 10 | 12 | 12 | 8 | ||||||
| Program Rights Obligations Noncurrent | 5 | 4 | 1 | 0 | 0 | 0 | 0 | 0 | - | - | - | - | ||||||
| Liabilities | 13 | 17 | 7 | 5 | 5 | 5 | 10 | 8 | - | 12 | 12 | - | ||||||
Stockholders Equity | ||||||||||||||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital | 937 | 936 | 785 | 688 | 684 | 681 | 676 | 670 | 662 | 655 | 646 | 636 | ||||||
| Retained Earnings Accumulated Deficit | -730 | -717 | -698 | -678 | -668 | -658 | -641 | -622 | -600 | -583 | -561 | -536 | ||||||
| Stockholders Equity | 207 | 219 | 87 | 9 | 16 | 22 | 36 | 48 | 61 | 72 | 85 | 101 | ||||||
| Liabilities And Stockholders Equity | 219 | 235 | 94 | 15 | 21 | 28 | 46 | 56 | 71 | 84 | 98 | 109 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - | - | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 200 | 200 | 200 | 200 | 200 | 200 | 200 | - | - | 200 | 200 | 4 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 200 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | ||||||
| Common Stock Shares Issued | 107 | 105 | 73 | 33 | 33 | 3 | 30 | 30 | 30 | 30 | 30 | 30 | ||||||
| Shares Outstanding | 107 | 105 | 73 | 33 | 33 | 33 | 30 | 30 | 30 | 30 | 30 | 30 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialRELMADA THERAPEUTICS, INC. (RLMD) — SEC Financial Statements & Analysis
RELMADA THERAPEUTICS, INC. (RLMD) is a pharmaceutical preparations company, incorporated in NV. RELMADA THERAPEUTICS, INC. trades on Nasdaq as: RLMD. RELMADA THERAPEUTICS, INC. (RLMD)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-06. Based on that filing, RELMADA THERAPEUTICS, INC. carries a market cap of $777.64M, a P/E ratio of -12.56x, a P/B ratio of 3.76x, an enterprise value of $766.31M, and an EV/EBITDA multiple of -11.77x. On profitability, it posts a Return on Equity (ROE) of -55.66%, a Return on Assets (ROA) of -51.57%, and a Return on Invested Capital (ROIC) of -62.08%. Per share, it reports EPS of $-0.55, diluted EPS of $-0.55, free cash flow per share of $-0.41, and a dividend per share of $0.00. Over the trailing year, it posted net income growth of -8.68% year-over-year and EPS growth of -73.03% year-over-year. On the balance sheet, it maintains a current ratio of 29.52x, a quick ratio of 29.34x, working capital of $211.62M, a debt-to-equity ratio of 0.06x, a debt ratio of 0.06, an interest coverage ratio of -72.78x, free cash flow of $-45.99M (TTM), and net debt of $-11.33M. Figures sourced from SEC EDGAR.
- Market Cap
- $777.64M
- P/E TTM
- -12.56x
- EPS TTM
- $-0.55
- P/B TTM
- 3.76x
- ROE TTM
- -55.66%
- ROA TTM
- -51.57%
- Debt To Equity
- 0.06x
- Free Cash Flow TTM
- $-45.99M
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is RELMADA THERAPEUTICS, INC. in?
RELMADA THERAPEUTICS, INC. (RLMD) operates in the Pharmaceutical Preparations industry.
What exchange does RLMD trade on?
RELMADA THERAPEUTICS, INC. (RLMD) trades on the Nasdaq.
Where is RELMADA THERAPEUTICS, INC. incorporated?
RELMADA THERAPEUTICS, INC. is incorporated in NV.
When was RELMADA THERAPEUTICS, INC. (RLMD)'s most recent SEC filing?
RELMADA THERAPEUTICS, INC. (RLMD)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-06.
What is RLMD's market cap?
RELMADA THERAPEUTICS, INC. (RLMD) has a market capitalization of $777.64M as of 2026-06-30.
What is RLMD's EPS (earnings per share)?
RELMADA THERAPEUTICS, INC. (RLMD)'s trailing twelve month EPS is $-0.55 as of 2026-06-30.
What is RLMD's ROE (return on equity)?
RELMADA THERAPEUTICS, INC. (RLMD)'s trailing twelve month Return on Equity (ROE) is -55.66% as of 2026-06-30.
What is RLMD's ROA (return on assets)?
RELMADA THERAPEUTICS, INC. (RLMD)'s trailing twelve month Return on Assets (ROA) is -51.57% as of 2026-06-30.
What is RLMD's ROIC (return on invested capital)?
RELMADA THERAPEUTICS, INC. (RLMD)'s trailing twelve month Return on Invested Capital (ROIC) is -62.08% as of 2026-06-30.
What is RLMD's EV/EBITDA?
RELMADA THERAPEUTICS, INC. (RLMD)'s trailing twelve month EV/EBITDA is -11.77x as of 2026-06-30.